secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001213900-22-071153
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics Q3 net loss $11.9M; cash $51M; positive JSP191 data in Fanconi Anemia
--------------------------------------------------------------------------------

- Net loss of $11.9M for Q3 2022 vs $3.4M in Q3 2021; R&D expenses $9.0M, G&A $3.7M.
- Cash and equivalents $51.0M as of Sept 30, 2022, expected to fund operations through early 2023.
- Positive clinical data: JSP191 conditioning achieved 100% donor chimerism in first two Fanconi Anemia patients.
- FDA Fast Track designation granted for JSP191 in Severe Combined Immunodeficiency (SCID) transplant.
- Registrational study in AML/MDS and new MDS second-line study expected to start Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390022071153/0001213900-22-071153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390022071153/ea168345-8k_jasperthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-071153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer